Bulk Pharma Group B
ID: 75A50325R00003Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEASPR/ORM-SNSAtlanta, GA, 30341, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
    Description

    The Department of Health and Human Services (HHS) is seeking proposals for the procurement of a range of FDA-approved pharmaceuticals as part of the Bulk Pharma Group B initiative. The contract will require the delivery of specific injectable medications, including Acyclovir Sodium, Doxycycline, Levophed, Meropenem, Sodium Chloride, and sterile water, with quantities detailed in the attached Request for Proposal (RFP). This procurement is critical for maintaining the Strategic National Stockpile, ensuring a reliable supply of essential pharmaceuticals for disaster preparedness and response efforts. Interested vendors must submit their proposals by the specified deadline, and inquiries can be directed to primary contact Terri Reed at terri.reed@hhs.gov or secondary contact Kimberly Golden at kimberly.golden1@hhs.gov.

    Point(s) of Contact
    Files
    Title
    Posted
    The document is a combined synopsis and solicitation for a federal government contract issued by the U.S. Department of Health and Human Services (HHS). The primary purpose is to procure pharmaceutical supplies for the Strategic National Stockpile, aimed at replenishing expired products. The solicitation number is 75A50325R00003, and it anticipates awarding a Firm Fixed Price type contract. There will be a base ordering period of 12 months, with four optional periods of the same duration. The acquisition is conducted under full and open competition and is not set aside for small businesses, with key details outlined including delivery locations and acceptance protocols. Supplementary sections detail the scope of supplies, evaluation criteria, and provisions necessary for contractor compliance, including specific terms related to performance evaluation, payment processing through electronic systems, and record-keeping obligations. Companies are required to submit proposals by the specified deadline, including a completed set of representations and certifications. Overall, this document lays the groundwork for the procurement process, emphasizing the necessity of pharmaceuticals in disaster preparedness and response efforts while adhering to existing federal regulations.
    The document pertains to the federal RFP (Request for Proposal) 75A50325R00003, focusing on the procurement of specific pharmaceutical products for the Bulk Pharma Group B. It outlines the technical specifications for various injectable medications including Acyclovir Sodium, Doxycycline, Levophed, Meropenem, Sodium Chloride, and sterile water for injection, designated for delivery over multiple option years. Suppliers are required to specify their company name, business size, and provide detailed information about product packaging, including National Drug Code (NDC) and National Stock Number (NSN) where applicable. The file also requests past performance details from bidders, highlighting the necessity of demonstrating relevant experience in similar projects within the last three years. It emphasizes providing comprehensive project descriptions, including contract information, work narratives, financial details, and relevant contacts. Compliance with the Trade Agreement Act and Buy American Act is mandatory, along with proof of manufacturing or certified reseller status. This RFP is part of the federal initiative to ensure a reliable supply chain for essential pharmaceuticals, focusing on quality, compliance, and past performance evaluation to select qualified vendors effectively.
    The document pertains to RFP 75A50325R00003 for Bulk Pharma Group B, outlining a business template required for pharmaceutical product proposals. It requests detailed information from offerors regarding various pharmaceutical items, including Acyclovir, Doxycycline, Levophed, Meropenem, Sodium Chloride, and Sterile Water, specifying unit quantities and pricing for multiple option years. The template mandates the completion of fields such as total quantities provided by the U.S. Government (USG) for each option year, manufacturing details like NDC numbers, vendor's pricing for each product, and extended price calculations. The purpose of this RFP is to procure essential injectable medications from qualified suppliers, ensuring that bids can be compared across submissions for suitability and cost-effectiveness. This structured approach facilitates transparency and compliance with government procurement standards while providing a clear breakdown of expected quantities and pricing for evaluation by the awarding agency.
    The document is a question and answer sheet associated with the Request for Proposal (RFP) identified as Solicitation No. 75A50325R00003. It serves as a platform for contractors to submit inquiries about the RFP. Each entry provides sections for contractors' questions, detailing references to specific sections, paragraphs, and pages of the solicitation language. The government's responses are consolidated and provided directly below each question, indicating continuity in communication regarding the requirements and clarifications needed by potential vendors. The structure allows for systematic tracking of questions and responses, ensuring transparency and thorough understanding of the solicitation process. Overall, this Q&A sheet is a vital component of the RFP process, facilitating clear dialogue between the government and contractors to refine proposals and enhance compliance with outlined solicitations.
    The section 52.212-3 outlines the Offeror Representations and Certifications specific to commercial products and services, primarily emphasizing compliance with government contracting requirements. It requires Offerors to complete necessary certifications electronically through the System for Award Management (SAM). Key definitions are provided, including those for economically disadvantaged businesses, prohibited child labor scenarios, and ownership classifications such as small business and veteran-owned businesses. The document mandates disclosures related to federal tax liabilities, previous contract compliance, and restrictions on operations relating to Sudan and Iran. Additionally, certifications for products' compliance with the Buy American Act and trade agreement regulations are to be included. The provisions underscore various contextual business classifications, mirroring regulations observed in government RFPs and grants. The purpose of this document is to ensure that entities engaging in federal contracts adhere to specific ethical, legal, and operational standards, fostering transparency and accountability within government procurement processes.
    The document appears to be related to federal and state procurement processes, specifically Request for Proposals (RFPs) and grants. It likely contains various details about initiatives aimed at soliciting contractor services or funding. Key topics may involve project objectives, eligibility criteria, application processes, deadlines, budget considerations, and reporting requirements. The structure of the document could include sections delineating the scope of work, evaluation criteria, and terms of agreement, thereby guiding organizations on how to respond effectively. Overall, the document emphasizes the importance of compliance with federal regulations and local laws in pursuit of funding opportunities. It underscores the federal government's commitment to transparent contracting, ensuring that selected proposals align with public policy goals and community needs. Stakeholders must carefully assess the outlined requirements and tailor their proposals to meet the specified objectives while adhering to all stipulated guidelines and deadlines.
    Lifecycle
    Title
    Type
    Bulk Pharma Group B
    Currently viewing
    Combined Synopsis/Solicitation
    Similar Opportunities
    FY25 Bulk Pharma Buy (Materiel)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), is seeking information from vendors regarding the procurement of pharmaceuticals for the Strategic National Stockpile (SNS) under the FY25 Bulk Pharma Buy initiative. The RFI aims to gather details on vendors' capabilities to supply FDA-approved pharmaceuticals, including Amoxicillin, Ciprofloxacin, and Clindamycin, which are critical for public health emergencies. This procurement is vital for ensuring rapid access to life-saving medical supplies during biological, chemical, and radiological threats, as well as natural disasters. Interested vendors must submit their responses electronically by January 8, 2025, and can direct inquiries to Terri Reed at terri.reed@hhs.gov.
    Doxycycline Hyclate Solicitation
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Doxycycline Hyclate tablets under solicitation number SPE2D2-25-R-0004. This procurement aims to secure pharmaceutical products in various quantities and packaging configurations, with specific requirements outlined for compliance with federal regulations, including business ethics and subcontracting plans. Doxycycline Hyclate is a critical antibiotic used in various medical applications, making this procurement essential for maintaining adequate supplies for military and healthcare operations. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Courtney Hunter-Stangler or Jason C. Wray for further information regarding the solicitation.
    Public Health Industrial Base Capabilities and Capacities: Anti-Microbials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking industry partners to provide information on domestic production capabilities related to anti-microbials as part of the Defense Production Act Title III Program. The objective is to gather data that will enhance the understanding of the Public Health Industrial Base (PHIB) and identify gaps in the marketplace that can be addressed through Title III authorities, which incentivize domestic production. This initiative is crucial for ensuring a reliable supply of essential health resources necessary for national defense and public health, particularly in light of the recent Presidential Determination 2024-03. Interested parties are invited to submit their responses by January 22, 2025, at 10 AM ET, to Chris Newell at IBMSC-Submissions@hhs.gov or Christopher.Newell@hhs.gov.
    6505--762-25-1-040-0284 -Tucson CMOP FEXOFENADINE -(VA-25-00020806)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Fexofenadine HCL 60MG (500CT) for the Tucson Consolidated Mail Outpatient Pharmacy (CMOP). Vendors are required to submit detailed quotes that include a signed SF1449 solicitation cover page, a completed pricing schedule, a valid wholesale distributor license, and OEM authorization for over-the-counter products, ensuring compliance with the Buy American Act and other regulatory standards. This pharmaceutical product is critical for treating allergies and must meet stringent quality and safety requirements, including a minimum shelf life of one year upon delivery. Proposals are due by January 10, 2025, at 3:00 PM CT, and interested vendors can contact Contract Specialist Jennifer D Coleman at jennifer.coleman4@va.gov for further information.
    6505--Baclofen Tablets (VA-25-00026620)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) 36E79725R0015 for the procurement of Baclofen Tablets, aimed at ensuring a reliable supply for various federal health facilities, including the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The procurement will cover a one-year contract with four additional pre-priced option years, requiring offerors to provide products labeled with their unique National Drug Code (NDC) numbers. This initiative is critical for maintaining uninterrupted access to essential medications for veterans and other federal health service users. Interested suppliers should note that the solicitation will be electronically posted on or around December 30, 2024, with a submission deadline of January 13, 2025; inquiries can be directed to Contract Specialist Adrienne A. Albachiara at adrienne.albachiara@va.gov.
    Request for Information - Enhancing Pharmacy Countermeasures in Independent Pharmacies
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking insights through a Request for Information (RFI) aimed at enhancing pharmacy countermeasures in independent pharmacies. The objective is to gather information from pharmacy partners, vendors, and associations regarding the necessary capabilities and infrastructure for independent pharmacies to effectively deliver health services, including testing, vaccines, and therapeutics, particularly to under-resourced populations. This initiative is crucial as independent pharmacies play a vital role in public health, especially in rural areas, and the information collected will inform strategies to improve service delivery and public health response capacity. Interested parties can contact Dawn Redman at dredman@cdc.gov or call 404-498-3069 for further details.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense (DoD) is seeking quotes for a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) related to the procurement of pharmaceutical agents as part of its Uniform Formulary (UF) initiative. This procurement aims to establish an effective and integrated pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of newly approved drugs, including neurological agents, antibiotics, oncological agents, and various other pharmaceutical categories. Interested manufacturers must submit their quotes by January 16, 2025, with a pre-quotation teleconference scheduled for January 8, 2025, to discuss the requirements and expectations. For further inquiries, manufacturers can contact Tracy Banks at tracy.e.banks2.civ@health.mil or Patricia Tyson at patricia.a.tyson3.ctr@health.mil.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug products. The objective of this procurement is to secure high-quality formulated drug products to support preclinical, IND-enabling, and clinical studies, ensuring compliance with current Good Manufacturing Practices (cGMP). This initiative is critical for advancing therapeutic development and enhancing the drug development pipeline, which is vital for public health. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can reach out to Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    Doxycycline Hyclate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    Access to Outpatient Longitudinal Drug Utilization Data
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide access to outpatient longitudinal drug utilization data through a Sources Sought notice. The primary objective is to acquire existing, HIPAA-compliant data resources that will enhance drug safety evaluations, support post-market surveillance, and inform regulatory decisions, rather than developing new databases. This initiative is crucial for monitoring medication utilization trends, particularly in areas such as opioid surveillance, and aims to improve public health outcomes through rigorous analyses of drug safety data. Interested firms must submit their responses by January 23, 2025, including their business size status and DUNS number, and can direct inquiries to Telisha Wilson at telisha.wilson@fda.hhs.gov.